Cy­to­Dyn faces DOJ, SEC sub­poe­nas af­ter pro­mot­ing failed Covid-19 drug

The lit­tle, PR-hap­py drug com­pa­ny pub­licly called out by the FDA is now get­ting at­ten­tion from both the SEC and the De­part­ment of Jus­tice.

Cy­to­Dyn, a one-time pen­ny stock that has gained both mon­ey and no­to­ri­ety for ag­gres­sive­ly push­ing an old HIV drug as a treat­ment for Covid-19, dis­closed in a reg­u­la­to­ry fil­ing Fri­day the SEC and DOJ have sep­a­rate­ly sub­poe­naed the com­pa­ny and “cer­tain of its ex­ec­u­tives” as part of in­ves­ti­ga­tions in­to the com­pa­ny’s pro­mo­tion and mar­ket­ing prac­tices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER